{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:42:13Z","timestamp":1792741333520,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.cct.2020.106225","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T21:40:24Z","timestamp":1605908424000},"page":"106225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Innovative trial designs and analyses for vaccine clinical development"],"prefix":"10.1016","volume":"100","author":[{"given":"Mengya","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2020.106225_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Deepak","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cct.2020.106225_bb0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/10543400600719251","article-title":"Statistical considerations for noninferiority\/equivalence trials in vaccine development","volume":"16","author":"Wang","year":"2006","journal-title":"J. Biopharm. Stat."},{"issue":"499","key":"10.1016\/j.cct.2020.106225_bb0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat0360","article-title":"Design of vaccine efficacy trials during public health emergencies","volume":"11","author":"Dean","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/j.cct.2020.106225_bb0020","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1214\/17-AOAS1095","article-title":"Design of vaccine trials during outbreaks with and without a delayed vaccination comparator","volume":"12","author":"Dean","year":"2018","journal-title":"Ann. Appl. Stat."},{"key":"10.1016\/j.cct.2020.106225_bb0025","series-title":"Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics","author":"Food and Drug Administration","year":"2019"},{"key":"10.1016\/j.cct.2020.106225_bb0030","series-title":"GARDASIL Highlights of Prescribing Information","author":"US Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.cct.2020.106225_bb0035","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"De Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cct.2020.106225_bb0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect. Agent Cancer"},{"issue":"1","key":"10.1016\/j.cct.2020.106225_bb0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1740774514552110","article-title":"A seamless phase IIB\/III adaptive outcome trial: design rationale and implementation challenges","volume":"12","author":"Chen","year":"2015","journal-title":"Clin. Trials"},{"issue":"2","key":"10.1016\/j.cct.2020.106225_bb0050","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12561-017-9202-3","article-title":"Population-enrichment adaptive design strategy for an event-driven vaccine efficacy trial","volume":"10","author":"Su","year":"2018","journal-title":"Stat. Biosci."},{"key":"10.1016\/j.cct.2020.106225_bb0055","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2020.106225_bb0060","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2307\/2533262","article-title":"Designed extension of studies based on conditional power","author":"Proschan","year":"1995","journal-title":"Biometrics"},{"issue":"4","key":"10.1016\/j.cct.2020.106225_bb0065","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2307\/2533441","article-title":"Evaluation of experiments with adaptive interim analyses","volume":"50","author":"Bauer","year":"1994","journal-title":"Biometrics"},{"issue":"4","key":"10.1016\/j.cct.2020.106225_bb0070","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/j.0006-341X.1999.01286.x","article-title":"Adaptive sample size calculations in group sequential trials","volume":"55","author":"Lehmacher","year":"1999","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.cct.2020.106225_bb0075","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.0006-341X.1999.00853.x","article-title":"Modification of sample size in group sequential clinical trials","volume":"55","author":"Cui","year":"1999","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.cct.2020.106225_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/pst.302","article-title":"Multiplicity and flexibility in clinical trials","volume":"6","author":"Brannath","year":"2007","journal-title":"Pharm. Stat."},{"issue":"7","key":"10.1016\/j.cct.2020.106225_bb0085","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/sim.1688","article-title":"Increasing the sample size when the unblinded interim result is promising","volume":"23","author":"Chen","year":"2004","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.cct.2020.106225_bb0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4310\/SII.2012.v5.n4.a2","article-title":"An adaptive design for case-driven vaccine efficacy study when incidence rate is unknown","volume":"5","author":"Li","year":"2012","journal-title":"Stat. Interface"},{"issue":"3","key":"10.1016\/j.cct.2020.106225_bb0095","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.0006-341X.2001.00886.x","article-title":"Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches","volume":"57","author":"M\u00fcller","year":"2001","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2020.106225_bb0100","series-title":"Interacting With the FDA on Complex Innovative Trial Designs for Drugs and Biological Products","author":"FDA","year":"2019"},{"issue":"3","key":"10.1016\/j.cct.2020.106225_bb0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0021-9681(76)90044-8","article-title":"The combination of randomized and historical controls in clinical trials","volume":"29","author":"Pocock","year":"1976","journal-title":"J. Chronic Dis."},{"issue":"1","key":"10.1016\/j.cct.2020.106225_bb0110","first-page":"46","article-title":"Power prior distributions for regression models","volume":"15","author":"Ibrahim","year":"2000","journal-title":"Stat. Sci."},{"issue":"1","key":"10.1016\/j.cct.2020.106225_bb0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/env.752","article-title":"Evaluating water quality using power priors to incorporate historical information","volume":"17","author":"Duan","year":"2006","journal-title":"Environmetrics"},{"issue":"28","key":"10.1016\/j.cct.2020.106225_bb0120","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1002\/sim.3722","article-title":"A note on the power prior","volume":"28","author":"Neuenschwander","year":"2009","journal-title":"Stat. Med."},{"issue":"1","key":"10.1016\/j.cct.2020.106225_bb0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1740774509356002","article-title":"Summarizing historical information on controls in clinical trials","volume":"7","author":"Neuenschwander","year":"2010","journal-title":"Clin. Trials"},{"issue":"4","key":"10.1016\/j.cct.2020.106225_bb0130","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/biom.12242","article-title":"Robust meta-analytic-predictive priors in clinical trials with historical control information","volume":"70","author":"Schmidli","year":"2014","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2020.106225_bb0135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1740774509339238","article-title":"Bayesian design using adult data to augment Pediatric trials","volume":"4","author":"Schoenfeld","year":"2009","journal-title":"Clin. Trials"},{"key":"10.1016\/j.cct.2020.106225_bb0140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/pst.1807","article-title":"Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation","volume":"16","author":"Gamalo-Siebers","year":"2017","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.cct.2020.106225_bb0145","doi-asserted-by":"crossref","DOI":"10.1080\/19466315.2020.1736617","article-title":"Bayesian approaches on borrowing historical data for vaccine efficacy trials","author":"Jin","year":"2020","journal-title":"Stat. Biopharm. Res."},{"key":"10.1016\/j.cct.2020.106225_bb0150","series-title":"Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials","author":"FDA","year":"2010"},{"issue":"3","key":"10.1016\/j.cct.2020.106225_bb0155","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin. Trials"},{"key":"10.1016\/j.cct.2020.106225_bb0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.106225_bb0165","series-title":"Adaptive Randomization for Master Protocols in Precision Medicine. Contemporary Biostatistics with Biopharmaceutical Application","first-page":"251","author":"Lin","year":"2019"},{"key":"10.1016\/j.cct.2020.106225_bb0170","series-title":"Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry","author":"FDA","year":"2018"},{"key":"10.1016\/j.cct.2020.106225_bb0175","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ctrv.2015.12.008","article-title":"Clinical trial designs incorporating predictive biomarkers","volume":"43","author":"Renfro","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cct.2020.106225_bb0180","author":"RECOVERY (Randomized Evaluation of COVID-19 Therapy)"},{"key":"10.1016\/j.cct.2020.106225_bb0185","author":"WHO"},{"key":"10.1016\/j.cct.2020.106225_bb0190","author":"Sunnybrook Health Sciences Centre"},{"key":"10.1016\/j.cct.2020.106225_bb0195","author":"REMAP-CAP (Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia)"},{"key":"10.1016\/j.cct.2020.106225_bb0200","author":"Australasian COVID-19 Trial (ASCOT)"},{"key":"10.1016\/j.cct.2020.106225_bb0205","author":"NIAID"},{"key":"10.1016\/j.cct.2020.106225_bb0210","series-title":"Bayesian Adaptive Methods for Clinical Trials","author":"Berry","year":"2010"},{"key":"10.1016\/j.cct.2020.106225_bb0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cct.2017.01.003","article-title":"Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials","volume":"54","author":"Lin","year":"2017","journal-title":"Contem. Clin. Trials."},{"key":"10.1016\/j.cct.2020.106225_bb0220","series-title":"Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Pandemic","author":"FDA","year":"2020"},{"key":"10.1016\/j.cct.2020.106225_bb0225","article-title":"Hybrid clinical trials to generate real-world evidence: design considerations from a sponsor's perspective","volume":"105856","author":"Zhu","year":"2019","journal-title":"Contemporary Clinical Trials"},{"issue":"4","key":"10.1016\/j.cct.2020.106225_bb0230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2020.106225_bb0235","author":"WHO"},{"key":"10.1016\/j.cct.2020.106225_bb0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.0006-341X.2002.00021.x","article-title":"Principal stratification in causal inference","volume":"58","author":"Frangakis","year":"2002","journal-title":"Biometrics"},{"issue":"9","key":"10.1016\/j.cct.2020.106225_bb0245","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/522428","article-title":"A framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"Qin","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.cct.2020.106225_bb0250","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1541-0420.2006.00569.x","article-title":"Augmented designs to assess immune response in vaccine trials","volume":"62","author":"Follmann","year":"2006","journal-title":"Biometrics"},{"issue":"4","key":"10.1016\/j.cct.2020.106225_bb0255","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1541-0420.2011.01603.x","article-title":"Comparing biomarkers as principal surrogate endpoints","volume":"67","author":"Huang","year":"2011","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.cct.2020.106225_bb0260","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/biom.12014","article-title":"Design and estimation for evaluating principal surrogate markers in vaccine trials","volume":"69","author":"Huang","year":"2013","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2020.106225_bb0265","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/0962280214565833","article-title":"Likelihood-based methods for evaluating principal surrogacy in augmented vaccine trials","volume":"26","author":"Liu","year":"2017","journal-title":"Stat. Methods Med. Res."},{"issue":"5","key":"10.1016\/j.cct.2020.106225_bb0270","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"The Journal of Infectious Diseases"},{"issue":"1","key":"10.1016\/j.cct.2020.106225_bb0275","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/19466315.2015.1093540","article-title":"Review of statistical innovations in trials supporting vaccine clinical development","volume":"8","author":"Heyse","year":"2016","journal-title":"Stat. Biopharm. Res."},{"key":"10.1016\/j.cct.2020.106225_bb0280","series-title":"Design and Analysis of Vaccine Studies","author":"Halloran","year":"2010"},{"issue":"2","key":"10.1016\/j.cct.2020.106225_bb0285","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/aje\/kwy239","article-title":"Analyzing vaccine trials in epidemics with mild and asymptomatic infection","volume":"188","author":"Kahn","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.cct.2020.106225_bb0290","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/sim.4780131803","article-title":"Reduction in burden of illness: a new measure in prevention trials","volume":"13","author":"Chang","year":"1994","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2020.106225_bb0295","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1541-0420.2005.00516.x","article-title":"A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof of-concept HIV vaccine trial","volume":"62","author":"Mehrotra","year":"2006","journal-title":"Biometrics"},{"issue":"11","key":"10.1016\/j.cct.2020.106225_bb0300","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/sim.6412","article-title":"Two-part test of vaccine effect","volume":"34","author":"Hu","year":"2015","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2020.106225_bb0305","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1541-0420.2008.01131.x","article-title":"Chop-lump tests for vaccine trials","volume":"65","author":"Follman","year":"2009","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2020.106225_bb0310","series-title":"Statistics in Clinical and Observational Vaccine Studies","author":"Nauta","year":"2020"},{"issue":"3","key":"10.1016\/j.cct.2020.106225_bb0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1191\/0962280204sm363ra","article-title":"Use of the false discovery rate for evaluating clinical safety data","volume":"13","author":"Mehrotra","year":"2004","journal-title":"Stat. Methods Med. Res."},{"issue":"2","key":"10.1016\/j.cct.2020.106225_bb0320","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.0006-341X.2004.00186.x","article-title":"Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model","volume":"60","author":"Berry","year":"2004","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.cct.2020.106225_bb0325","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/biom.12324","article-title":"Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance","volume":"71","author":"Silva","year":"2015","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.cct.2020.106225_bb0330","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/07474946.2011.539924","article-title":"A maximized sequential probability ratio test for drug and vaccine safety surveillance","volume":"30","author":"Kulldorff","year":"2011","journal-title":"Seq. Anal."},{"issue":"3","key":"10.1016\/j.cct.2020.106225_bb0335","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pst.1991","article-title":"A Bayesian approach to sequential analysis in post-licensure vaccine safety surveillance","volume":"19","author":"Li","year":"2020","journal-title":"Pharm. Stat."},{"issue":"13","key":"10.1016\/j.cct.2020.106225_bb0340","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/sim.820","article-title":"Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials","volume":"20","author":"Wang","year":"2001","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.cct.2020.106225_bb0345","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1081\/BIP-200035454","article-title":"Type I error and power in noninferiority\/equivalence trials with correlated multiple endpoints: an example from vaccine development trials","volume":"14","author":"Kong","year":"2004","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.cct.2020.106225_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106096","article-title":"Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies","author":"Li","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.cct.2020.106225_bb0355","author":"Pfizer"},{"key":"10.1016\/j.cct.2020.106225_bb0360","article-title":"Practical considerations of utilizing propensity score methods in clinical development using real-world and historical data","volume":"106123","author":"Li","year":"2020","journal-title":"Contemp. Clin. Trials"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420303037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420303037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:49:51Z","timestamp":1761554991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714420303037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":72,"alternative-id":["S1551714420303037"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2020.106225","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative trial designs and analyses for vaccine clinical development","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2020.106225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106225"}}